메뉴 건너뛰기




Volumn 15, Issue 12, 2010, Pages 1335-1343

The European medicines agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: Summary of the scientific assessment of the European medicines agency committee for medicinal products for human use

Author keywords

Chronic lymphocytic leukemia; CLL; EMA; European medicines agency; Ofatumumab

Indexed keywords

ALEMTUZUMAB; CD20 ANTIBODY; CD20 ANTIGEN; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C5A; FLUDARABINE; OFATUMUMAB; RITUXIMAB;

EID: 78650980278     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0255     Document Type: Review
Times cited : (20)

References (10)
  • 1
    • 0034649696 scopus 로고    scopus 로고
    • Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia
    • Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750-1757.
    • (2000) N Engl J Med , vol.343 , pp. 1750-1757
    • Rai, K.R.1    Peterson, B.L.2    Appelbaum, F.R.3
  • 2
    • 34447530283 scopus 로고    scopus 로고
    • Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukemia (the LRF CLL4 Trial): A randomised controlled trial
    • Catovsky D, Richards S, Matutes E et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukemia (the LRF CLL4 Trial): A randomised controlled trial. Lancet 2007;370:230-239.
    • (2007) Lancet , vol.370 , pp. 230-239
    • Catovsky, D.1    Richards, S.2    Matutes, E.3
  • 3
    • 23044501404 scopus 로고    scopus 로고
    • Chemoimmunotherapy with fludarabine, cyclophoshamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
    • Wierda W, O'Brien S, Wen S et al. Chemoimmunotherapy with fludarabine, cyclophoshamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005;23:4070-4078.
    • (2005) J Clin Oncol , vol.23 , pp. 4070-4078
    • Wierda, W.1    O'Brien, S.2    Wen, S.3
  • 4
    • 0034727833 scopus 로고    scopus 로고
    • Genomic aberrations and survival in chronic lymphocytic leukemia
    • Döhner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-1916.
    • (2000) N Engl J Med , vol.343 , pp. 1910-1916
    • Döhner, H.1    Stilgenbauer, S.2    Benner, A.3
  • 5
    • 0035676926 scopus 로고    scopus 로고
    • Complement activation plays a key role in the side-effects of rituximab treatment
    • van der Kolk LE, Grillo-López AJ, Baars JW et al. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001;115:807-811.
    • (2001) Br J Haematol , vol.115 , pp. 807-811
    • van der Kolk, L.E.1    Grillo-López, A.J.2    Baars, J.W.3
  • 6
    • 0031962079 scopus 로고    scopus 로고
    • Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment
    • Deans JP, Robbins SM, Polyak MJ et al. Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment. J Biol Chem 1998;273:344-348.
    • (1998) J Biol Chem , vol.273 , pp. 344-348
    • Deans, J.P.1    Robbins, S.M.2    Polyak, M.J.3
  • 7
    • 4444343395 scopus 로고    scopus 로고
    • Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas
    • Teeling JL, French RR, Cragg MS et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004;104:1793-1800.
    • (2004) Blood , vol.104 , pp. 1793-1800
    • Teeling, J.L.1    French, R.R.2    Cragg, M.S.3
  • 8
    • 38949185742 scopus 로고    scopus 로고
    • Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: A phase 1-2 study
    • Coiffier B, Lepretre S, Pedersen LM et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: A phase 1-2 study. Blood 2008;111:1094-1100.
    • (2008) Blood , vol.111 , pp. 1094-1100
    • Coiffier, B.1    Lepretre, S.2    Pedersen, L.M.3
  • 9
    • 0029981025 scopus 로고    scopus 로고
    • National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment
    • Cheson BD, Bennett JM, Grever M et al. National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 1996;87:4990-4997.
    • (1996) Blood , vol.87 , pp. 4990-4997
    • Cheson, B.D.1    Bennett, J.M.2    Grever, M.3
  • 10
    • 77950502126 scopus 로고    scopus 로고
    • Hx-CD20-406 Study Investigators. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia
    • Wierda WG, Kipps TJ, Mayer J et al. Hx-CD20-406 Study Investigators. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:1749-1755.
    • (2010) J Clin Oncol , vol.28 , pp. 1749-1755
    • Wierda, W.G.1    Kipps, T.J.2    Mayer, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.